Lake Street analyst Frank Takkinen raised the firm’s price target on Inspire Medical to $350 from $305 and keeps a Buy rating on the shares. After the company reported Q2 results and management increased 2023 revenue guidance, Lake Street says that Inspire “continues to execute exceptionally well.” The firm thinks the company is “in the early innings of penetrating the uncontended $10B obstructive sleep apnea,” the analyst added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Inspire Medical raises FY23 revenue view to $600M-$610M from $580M-$590M
- Inspire Medical reports Q2 EPS (41c), consensus (57c)
- Inspire Medical Systems, Inc. Announces Second Quarter 2023 Financial Results and Updates 2023 Outlook
- Inspire Medical appoints Charisse Sparks as CMO
- Is INSP a Buy, Before Earnings?